These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38261390)

  • 41. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
    Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
    Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
    Rodziewicz M; Dyball S; Lunt M; McDonald S; Sutton E; Parker B; Bruce IN;
    Lancet Rheumatol; 2023 May; 5(5):e284-e292. PubMed ID: 38251591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.
    Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Luo SF; Wu YJ; Cho J; Lateef A; Lau CS; Chen YH; Navarra S; Zamora L; Li Z; An Y; Sockalingam S; Hao Y; Zhang Z; Chan M; Katsumata Y; Harigai M; Oon S; Bae SC; O'Neill S; Gibson KA; Basnayake B; Kikuchi J; Takeuchi T; Ng KPL; Tugnet N; Kumar S; Goldblatt F; Law A; Tee M; Tee C; Tanaka Y; Ohkubo N; Tan JY; Karyekar CS; Nikpour M; Golder V; Morand EF
    Arthritis Rheumatol; 2023 Mar; 75(3):401-410. PubMed ID: 36122172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
    de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
    Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE.
    Cody EM; Wilson BE; Ogbu EA; Huggins JL; Chen C; Qiu T; Ting TV; Flores F; Huang B; Brunner HI
    Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37253553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
    Babaoglu H; Li J; Goldman D; Magder LS; Petri M
    Lupus; 2019 Dec; 28(14):1648-1655. PubMed ID: 31694446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low disease activity state in juvenile-onset systemic lupus erythematosus.
    Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
    Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
    Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
    Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
    Morand EF; Isenberg DA; Wallace DJ; Kao AH; Vazquez-Mateo C; Chang P; Pudota K; Aranow C; Merrill JT
    Rheumatology (Oxford); 2020 Oct; 59(10):2930-2938. PubMed ID: 32107560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epstein-Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement.
    Miskovic R; Cirkovic A; Miljanovic D; Jeremic I; Grk M; Basaric M; Lazarevic I; Stojanovic M; Plavsic A; Raskovic S; Banko A
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up.
    Parodis I; Stephens T; Dominicus A; Eek D; Sjöwall C
    Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38402496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pregnancy outcomes between pregnant systemic lupus erythematosus patients with clinical remission and those with low disease activity: A comparative study.
    Louthrenoo W; Trongkamolthum T; Kasitanon N; Wongthanee A
    Arch Rheumatol; 2022 Sep; 37(3):361-374. PubMed ID: 36589601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) Registry XI: gender impact on long-term outcomes.
    Zhang S; Ye Z; Li C; Li Z; Li X; Wu L; Liu S; Zuo X; Zhu P; Wang Z; Wang Y; Wang Z; Zhao J; Wang Q; Tian X; Li M; Zeng X
    Lupus; 2019 Apr; 28(5):635-641. PubMed ID: 30939980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.